Prognostic Factors and Morbidities After Completion Surgery in Patients Undergoing Initial Chemoradiation Therapy for Locally Advanced Cervical Cancer

被引:78
|
作者
Touboul, Cyril [2 ]
Uzan, Catherine [2 ]
Mauguen, Audrey [3 ]
Gouy, Sebastien [2 ]
Rey, Annie [3 ]
Pautier, Patricia [4 ]
Lhomme, Catherine [4 ]
Duvillard, Pierre [6 ]
Haie-Meder, Christine [5 ]
Morice, Philippe [1 ,2 ]
机构
[1] Univ Paris Sud, Inst Gustave Roussy, F-94805 Villejuif, France
[2] Dept Gynecol Surg, Villejuif, France
[3] Dept Biostat, Villejuif, France
[4] Dept Oncol, Villejuif, France
[5] Dept Pathol, Villejuif, France
[6] Inst Gustave Roussy, Dept Radiotherapy, F-94805 Villejuif, France
来源
ONCOLOGIST | 2010年 / 15卷 / 04期
关键词
Chemoradiation therapy; Completion surgery; Locally advanced cervical cancer; Morbidities; Nodal involvement; Prognostic factors; Residual disease; Survival; POSITRON-EMISSION-TOMOGRAPHY; GYNECOLOGIC-ONCOLOGY-GROUP; LYMPH-NODE INVOLVEMENT; BULKY RESIDUAL DISEASE; RADIATION-THERAPY; UTERINE CERVIX; PARAAORTIC LYMPHADENECTOMY; STAGE IB; CONCOMITANT CHEMORADIOTHERAPY; RADICAL HYSTERECTOMY;
D O I
10.1634/theoncologist.2009-0295
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose. The aim of this study was to evaluate the prognostic factors and morbidities of patients undergoing completion surgery for locally advanced-stage cervical cancer after initial chemoradiation therapy (CRT). Patients and Methods. Patients fulfilling the following inclusion criteria were studied: stage IB2-IVA cervical carcinoma, tumor initially confined to the pelvic cavity on conventional imaging, pelvic external radiation therapy with delivery of 45 Gy to the pelvic cavity and concomitant chemotherapy (cisplatin, 40 mg/m(2) per week) followed by uterovaginal brachytherapy, and completion surgery after the end of radiation therapy including at least a hysterectomy. Results. One-hundred fifty patients treated in 19982007 fulfilled the inclusion criteria. Prognostic factors for overall survival in the multivariate analysis were the presence and level of nodal spread (positive pelvic nodes alone: hazard ratio [HR], 2.03; positive para-aortic nodes: HR, 5.46; p < .001) and the presence and size of residual disease (RD) in the cervix (p = .02). Thirty-seven (25%) patients had 55 postoperative complications. The risk for complications was higher with a radical hysterectomy (p = .04) and the presence of cervical RD (p = .01). Conclusion. In this series, the presence and size of RD and histologic nodal involvement were the strongest prognostic factors. Such results suggest that the survival of patients treated using CRT for locally advanced cervical cancer could potentially be enhanced by improving the rate of complete response in the irradiated area (cervix or pelvic nodes) and by initially detecting patients with para-aortic spread so that treatment could be adapted in such patients. The morbidity of completion surgery is high in this context. The Oncologist 2010; 15: 405-415
引用
收藏
页码:405 / 415
页数:11
相关论文
共 50 条
  • [31] Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer
    Tangjitgamol, Siriwan
    Katanyoo, Kanyarat
    Laopaiboon, Malinee
    Lumbiganon, Pisake
    Manusirivithaya, Sumonmal
    Supawattanabodee, Busaba
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (12):
  • [32] Prognostic factors for disease-free and overall survival in patients treated with chemoradiation therapy for locally advanced pancreatic cancer
    Krishnan, S.
    Rana, V.
    Janjan, N.
    Abbruzzese, J.
    Das, P.
    Delclos, M.
    Varadhachary, G.
    Evans, D.
    Wolff, R.
    Crane, C.
    RADIOTHERAPY AND ONCOLOGY, 2006, 81 : S527 - S527
  • [33] Prognostic value of Naples prognostic score in locally advanced cervical cancer patients undergoing concurrent chemoradiotherapy
    Zhang, Xiaojun
    Gu, Mengxuan
    Zhu, Jiahao
    Gu, Ruike
    Yang, Bo
    Ji, Shengjun
    Zhao, Yutian
    Gu, Ke
    BIOMOLECULES AND BIOMEDICINE, 2024,
  • [34] Prognostic factors after preoperative irradiation and surgery for locally advanced rectal cancer
    Larsen, S. G.
    Wiig, J. N.
    Dueland, S.
    Giercksky, K. -E.
    EJSO, 2008, 34 (04): : 410 - 417
  • [35] Outcomes and prognostic factors of cervical cancer after concurrent chemoradiation
    Kim, Tae-Eung
    Park, Byung-Joon
    Kwack, Hyun-Sung
    Kwon, Ji-Young
    Kim, Jang-Heub
    Yoon, Sei-Chul
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2012, 38 (11) : 1315 - 1320
  • [36] Timing of Surgery after Induction Chemoradiation Therapy for Locally Advanced NSCLC
    Melek, Huseyin
    Demir, Adalet
    Cetinkaya, Gamze
    Ozkan, Berker
    Sarihan, Sureyya
    Eroi, Mehmet
    Bayram, Ahmet Sami
    Toker, Alper
    Gebitekin, Cengiz
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S767 - S767
  • [37] CERVICAL BIOPSY AFTER CHEMORADIATION FOR LOCALLY ADVANCED CERVICAL CANCER TO IDENTIFY RESIDUAL DISEASE
    Hoeijmakers, Y.
    Zusterzeel, P.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 768 - 768
  • [38] Thromboprophylaxis in patients with locally advanced cervical cancer treated with chemoradiation and brachytherapy
    Leijtens, Lisa
    Piek, Jurgen
    Verrijssen, An-Sofie
    Rijkaart, Dorien
    Wortman, Bastiaan
    Oele-Egelmeer, Ada
    Daniels-Gooszen, Alette
    Thijs, Annemarie
    Nijziel, Marten
    Kolfschoten, Sylvie
    Bekkers, Ruud
    Cnossen, Jeltsje
    GYNECOLOGIC ONCOLOGY, 2025, 193 : 41 - 48
  • [39] Prognostic value of 18F-FDG PET/CT in restaging of locally advanced cervical cancer after concomitant chemoradiation therapy
    Lima, G. M.
    Matti, A.
    De Crescenzo, E.
    Polverari, G.
    Perrone, A. M.
    De Iaco, P.
    Nanni, C.
    Fanti, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S231 - S232
  • [40] Predictors of Radiation Field Failure After Definitive Chemoradiation in Patients With Locally Advanced Cervical Cancer
    Bae, Hyo Sook
    Kim, Yeon-Joo
    Lim, Myong Cheol
    Seo, Sang-Soo
    Park, Sang-yoon
    Kang, Sokbom
    Kim, Sun Ho
    Kim, Joo-Young
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 (04) : 737 - 742